Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12781194rdf:typepubmed:Citationlld:pubmed
pubmed-article:12781194lifeskim:mentionsumls-concept:C0205145lld:lifeskim
pubmed-article:12781194lifeskim:mentionsumls-concept:C0001128lld:lifeskim
pubmed-article:12781194lifeskim:mentionsumls-concept:C0001465lld:lifeskim
pubmed-article:12781194lifeskim:mentionsumls-concept:C0016755lld:lifeskim
pubmed-article:12781194lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:12781194lifeskim:mentionsumls-concept:C1706498lld:lifeskim
pubmed-article:12781194pubmed:issue12lld:pubmed
pubmed-article:12781194pubmed:dateCreated2003-6-3lld:pubmed
pubmed-article:12781194pubmed:abstractText3-(2-Carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid (MDL-29951), an antagonist of the glycine site of the NMDA receptor, has been found to be an allosteric inhibitor of the enzyme fructose 1,6-bisphosphatase. The compound binds at the AMP regulatory site by X-ray crystallography. This represents a new approach to inhibition of fructose 1,6-bisphosphatase and serves as a lead for further drug design.lld:pubmed
pubmed-article:12781194pubmed:languageenglld:pubmed
pubmed-article:12781194pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12781194pubmed:citationSubsetIMlld:pubmed
pubmed-article:12781194pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12781194pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12781194pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12781194pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12781194pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12781194pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12781194pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12781194pubmed:statusMEDLINElld:pubmed
pubmed-article:12781194pubmed:monthJunlld:pubmed
pubmed-article:12781194pubmed:issn0960-894Xlld:pubmed
pubmed-article:12781194pubmed:authorpubmed-author:DanleyDennis...lld:pubmed
pubmed-article:12781194pubmed:authorpubmed-author:PanditJayvard...lld:pubmed
pubmed-article:12781194pubmed:authorpubmed-author:SchulteGayle...lld:pubmed
pubmed-article:12781194pubmed:authorpubmed-author:TreadwayJudit...lld:pubmed
pubmed-article:12781194pubmed:authorpubmed-author:WrightStephen...lld:pubmed
pubmed-article:12781194pubmed:authorpubmed-author:CarloAnthony...lld:pubmed
pubmed-article:12781194pubmed:authorpubmed-author:HagemanDavid...lld:pubmed
pubmed-article:12781194pubmed:authorpubmed-author:KaramGeorge...lld:pubmed
pubmed-article:12781194pubmed:authorpubmed-author:MansourMahmou...lld:pubmed
pubmed-article:12781194pubmed:authorpubmed-author:McClureLester...lld:pubmed
pubmed-article:12781194pubmed:authorpubmed-author:WangIng-KaeIKlld:pubmed
pubmed-article:12781194pubmed:authorpubmed-author:BauerPaul HPHlld:pubmed
pubmed-article:12781194pubmed:issnTypePrintlld:pubmed
pubmed-article:12781194pubmed:day16lld:pubmed
pubmed-article:12781194pubmed:volume13lld:pubmed
pubmed-article:12781194pubmed:ownerNLMlld:pubmed
pubmed-article:12781194pubmed:authorsCompleteYlld:pubmed
pubmed-article:12781194pubmed:pagination2055-8lld:pubmed
pubmed-article:12781194pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:meshHeadingpubmed-meshheading:12781194...lld:pubmed
pubmed-article:12781194pubmed:year2003lld:pubmed
pubmed-article:12781194pubmed:articleTitle3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site.lld:pubmed
pubmed-article:12781194pubmed:affiliationPfizer Central Research, Eastern Point Road, Box 8220-3141, Groton, CT 06340, USA. stephen_w_wright@groton.pfizer.comlld:pubmed
pubmed-article:12781194pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:12781194lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12781194lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12781194lld:pubmed